Oruka Therapeutics (ORKA) EPS (Diluted) Growth (3y) (2013 - 2024)
Powered by 
Analysis
Oruka Therapeutics (ORKA) EPS (Diluted) Growth (3y) (2013 - 2024) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 7.01% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.90% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 82.91% |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 18.44% |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 36.83% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 36.39% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -36.81% |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 67.51% |
| 10 | Oruka Therapeutics | 5.89 Bn | 4.16 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 18.05% |
| Mar 31, 2024 | 91.84% |
| Dec 31, 2023 | 92.67% |
| Sep 30, 2023 | 90.72% |
| Jun 30, 2023 | 89.17% |
| Mar 31, 2023 | 89.56% |
| Dec 31, 2022 | 82.44% |
| Sep 30, 2022 | 86.89% |
| Jun 30, 2022 | 86.52% |
| Mar 31, 2022 | 87.00% |
| Dec 31, 2021 | -26.93% |
| Sep 30, 2021 | 85.11% |
| Jun 30, 2021 | 86.34% |
| Mar 31, 2021 | -14.45% |
| Dec 31, 2020 | 10.17% |
| Sep 30, 2020 | 23.42% |
| Jun 30, 2020 | 38.22% |
| Mar 31, 2020 | 32.74% |
| Dec 31, 2019 | 61.51% |
| Sep 30, 2019 | 37.16% |